Regeneron and sonoma biotherapeutics announce collaboration to discover, develop and commercialize treg cell therapies for autoimmune diseases

Sonoma biotherapeutics to receive $75 million upfront, inclusive of $45 million cash and $30 million equity investment; potential for an additional $45 million development milestone payment sonoma biotherapeutics to receive $75 million upfront, inclusive of $45 million cash and $30 million equity investment; potential for an additional $45 million development milestone payment
REGN Ratings Summary
REGN Quant Ranking